Print Page | Close Window


June 23, 2017 - 7:36 a.m.
European CHMP Adopts Positive Opinion for Gilead’s Vosevi® (Sofosbuvir/Velpatasvir/Voxilaprevir) for the Treatment of All Chronic Hepatitis C Genotypes
Printer Friendly Version 
June 12, 2017 - 8:17 a.m.
Gilead Submits New Drug Application to U.S. Food and Drug Administration for Fixed-Dose Combination of Bictegravir, Emtricitabine and Tenofovir Alafenamide for HIV Treatment
Printer Friendly Version 
June 01, 2017 - 5:01 p.m.
Gilead Sciences to Present at the Goldman Sachs 38th Annual Global Healthcare Conference on Thursday, June 15
Printer Friendly Version 
May 30, 2017 - 5:01 p.m.
Gilead Sciences to Present at the 37th Annual William Blair Growth Stock Conference on Tuesday, June 13
Printer Friendly Version 
May 30, 2017 - 8:31 a.m.
Gilead’s Investigational Fixed-Dose Combination of Bictegravir, Emtricitabine and Tenofovir Alafenamide for the Treatment of HIV-1 Meets Primary Endpoint in Four Phase 3 Studies
Printer Friendly Version 
May 04, 2017 - 5:01 p.m.
Gilead Sciences to Present at the Bank of America Merrill Lynch Healthcare Conference on Thursday, May 18
Printer Friendly Version 
May 02, 2017 - 4:03 p.m.
Gilead Sciences Announces Second Quarter 2017 Dividend
Printer Friendly Version 
May 02, 2017 - 4:03 p.m.
Gilead Sciences Announces First Quarter 2017 Financial Results
Printer Friendly Version 
April 21, 2017 - 12:01 p.m.
Gilead Announces Scientific Presentations Demonstrating Efficacy of Harvoni® (Ledipasvir/Sofosbuvir) in Special Patient Populations With HCV Infection
Printer Friendly Version 
April 21, 2017 - 4:31 a.m.
Gilead Presents Proof-of-Concept Data for GS-0976 in Nonalcoholic Steatohepatitis (NASH) at The International Liver Congress™ 2017
Printer Friendly Version 
April 20, 2017 - 12:01 p.m.
Gilead Presents Data at the International Liver Congress™ 2017 Supporting the Efficacy and Safety of Vemlidy in Patients with Chronic Hepatitis B After 96 Weeks, and Also After Switching From Viread
Printer Friendly Version 
April 20, 2017 - 9:31 a.m.
Gilead to Present Clinical and Preclinical Data on Nonalcoholic Steatohepatitis (NASH) at The International Liver Congress™ 2017
Printer Friendly Version 
April 18, 2017 - 5:02 p.m.
Gilead Sciences to Release First Quarter 2017 Financial Results on Tuesday, May 2, 2017
Printer Friendly Version 
April 07, 2017 - 10:11 a.m.
U.S. FDA Approves New Indications for Harvoni® and Sovaldi® in Pediatric Patients 12 Years and Older with Chronic Hepatitis C Infection
Printer Friendly Version 
February 28, 2017 - 5:01 p.m.
Gilead Sciences to Present at the Barclays Global Healthcare Conference on Tuesday, March 14
Printer Friendly Version 
February 14, 2017 - 7:01 p.m.
Gilead Announces 144-Week Data Evaluating Safety and Efficacy of Genvoya® for Treatment of HIV-1 in Treatment-Naïve Adults
Printer Friendly Version 
February 13, 2017 - 6:47 p.m.
Gilead Announces Findings from New Preclinical Study Evaluating Novel Class of HIV Capsid Inhibitors
Printer Friendly Version 
February 13, 2017 - 6:47 p.m.
Gilead Presents New Phase 2 Data on Bictegravir, an Investigational Integrase Strand Transfer Inhibitor for the Treatment of HIV
Printer Friendly Version 
February 08, 2017 - 7:18 p.m.
Gilead Sciences to Present at the RBC Capital Markets 2017 Global Healthcare Conference on Wednesday, February 22
Printer Friendly Version 
February 07, 2017 - 4:04 p.m.
Gilead Sciences Announces 10 Percent Increase in First Quarter 2017 Dividend
Printer Friendly Version 
February 07, 2017 - 4:02 p.m.
Gilead Sciences Announces Fourth Quarter and Full Year 2016 Financial Results
Printer Friendly Version 
January 24, 2017 - 5:02 p.m.
Gilead Sciences to Release Fourth Quarter and Full Year 2016 Financial Results on Tuesday, February 7, 2017
Printer Friendly Version 
January 20, 2017 - 5:49 a.m.
European Medicines Agency Validates Gilead’s Marketing Authorization Application for Investigational Chronic Hepatitis C Therapy Sofosbuvir/Velpatasvir/Voxilaprevir (SOF/VEL/VOX)
Printer Friendly Version 
January 11, 2017 - 6:53 a.m.
European Commission Grants Marketing Authorization for Gilead’s Vemlidy® (Tenofovir Alafenamide, TAF) for the Treatment of Chronic Hepatitis B Virus Infection
Printer Friendly Version 
January 10, 2017 - 9:01 a.m.
Gilead Awards More Than $22 Million in Grants to Support HIV Cure Research
Printer Friendly Version 
January 03, 2017 - 4:31 p.m.
Alessandro Riva, MD, to Join Gilead as Senior Vice President, Hematology and Oncology Therapeutic Area Head
Printer Friendly Version